Al Altomari

Agile Therapeutics, President and Chief Executive Officer Al Altomari is the President and Chief Executive Officer of Agile Therapeutics and a member of the Company’s Board of Directors. Prior to being named President and CEO, Mr. Altomari served as Agile’s Executive Chairman in which capacity he closed a $45 million venture round in May 2010…. Read the full article


Marc Bonnefoi, DVM, Ph.D.

Sanofi, Head, North America R&D Hub and Global Head, Drug Disposition, Preclinical Safety and Animal Research Marc Bonnefoi is Head of Sanofi’ s North America R&D Hub which includes the R&D activities of Genzyme, Merial, Pharma, and Sanofi-Pasteur in the region. He also heads the global Scientific Core Platform Drug Disposition, Preclinical Safety and Animal… Read the full article


John F. Crowley

Amicus Therapeutics, Inc., Chairman and Chief Executive Officer John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc.  John’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease-a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his… Read the full article


Pamela M. Demain, MBA, CLP

Merck & Co., Inc., Executive Director, Transactions, Business Development and Licensing  Pamela Demain is Executive Director, Transactions, Business Development and Licensing, Merck & Co., Inc.  She has been at Merck for over 30 years. For the past 19 years, she has been responsible for negotiating transactions with companies, universities and institutions worldwide, including arrangements for… Read the full article


John Haney

Johnson & Johnson/Janssen Biotech, Vice President, Immunology Marketing John began his career with Johnson & Johnson 24 years ago and has enjoyed a broad and diverse career holding various sales and marketing leadership positions across the Johnson & Johnson family of companies.



Will Lewis

Insmed Incorporated, President and Chief Executive Officer Will joined Insmed in September 2012 as President and Chief Executive Officer and as a member of the Board of Directors. Will has more than 20 years of executive experience and a track record of success in the pharmaceutical and finance industries both in the US and internationally.


John Maki

Vicus Therapeutics, President and Chief Executive Officer John Maki previously served as Managing Director of Technology Directors, Inc., as Managing Director of Audax Group and as Principal, Bain Capital, as well as consultant, Bain & Company.


Anthony Marucci, MBA

Celldex Therapeutics, Inc., Founder, President, Chief Executive Officer and Director Mr. Marucci is a Founder of Celldex and served as its Vice President, Chief Financial Officer, Treasurer and Secretary since inception and prior to his appointments to Executive Vice President in March 2008, President and Chief Executive Officer in October 2008, and the Board of… Read the full article


David Pearson, Ph.D., MBA

ThromboGenics, Inc., President and Global Head of Corporate Development David Pearson, Ph.D., MBA, is an accomplished biopharmaceutical industry executive with more than 25 years of senior management experience in technical, operational and general management roles.  His passion has been the creation of innovative solutions to business, competitive and team challenges, while bridging the R&D, commercial… Read the full article